SBRT vs standard care for prostate cancer that has spread to a few spots
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether targeted radiation (SBRT) to a few sites of cancer spread can help men whose prostate cancer has stopped responding to hormone therapy but has not spread to many places. You may benefit if you have a limited number of growing spots outside the brain or spine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have been diagnosed with prostate cancer that has stopped responding to hormone therapy
- You have 9 or fewer spots of cancer spread outside the brain or spine that are growing
- You have been on any type of cancer treatment for more than 3 months
- Your doctor says you can safely get targeted radiation to all the growing spots
- You are able to care for yourself and walk (or have a condition that allows mild activity)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a precise type of radiation called SBRT can control lung cancer that has started to grow in only a few new spots while you are on standard treatments. It may help you delay changing to a different treatment.
This trial tests whether giving focused, high-dose radiation to spots where the cancer is growing can help control the disease while you stay on your current hormone therapy and/or CDK4/6 inhibitor. It is for people with ER+/HER2- breast cancer that has spread to a few places and is slowly starting to progress.
This study tests whether a very focused type of radiation (SABR) can control a small number of prostate cancer spots that are starting to grow while you’re already on abiraterone. It may help by treating only the areas that are progressing, while other areas remain controlled.
This trial studies whether adding focused radiation (SBRT) to hormone therapy can control prostate cancer that has spread to only a few places. It aims to help people with early “oligometastatic” prostate cancer by improving disease control while limiting treatment side effects.
This trial studies the use of radiation to the prostate and to all visible spots where cancer has spread, in men who have up to 10 small areas of spread when first diagnosed. The goal is to see if this approach can help control the cancer.
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
Hear when a new OligoProgressive Metastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.